A New Approach for the Immunodiagnostics of Breast Cancer by Random Peptide Phage Display
Abstract
We proposed to develop a new approach for tumor-specific antibody detection based on Random Peptide Phage Display (RPPD) technology and verify whether such assays could be applied in the context of breast cancer, to determine the immunogenic spectrum of these patients. The relevance of our study was based on the obvious burden represented by this disease in terms of frequency and morbidity and the potential benefit that the development of new diagnostic, prognostic and therapeutic strategies can provide. During this grant period we have developed RPPD assays that effectively select mimotopes specifically present in sera from cancer patients. Even more exciting is the fact that homology searches have revealed that most of the selected peptides are present in known cancer-related protein 5, thus unveiling potential new candidate tumor-antigens. We have also observed cross-reactivity of certain peptides with other patients hosting the same tumor type. These results set an ideal scenario for 1) The application of this methodology in the individual analysis of breast cancer patients' immune response and 2) the pursuit of large breast cancer series screening in order to detect new tumor antigens commonly present in these patients, as anticipated in TASKS 2 and 3 of our proposal.
Document Details
- Document Type
- Technical Report
- Publication Date
- Jul 01, 2000
- Accession Number
- ADA389421
Entities
People
- Manuel Perucho
Organizations
- Sanford Burnham Prebys Medical Discovery Institute